Drugs / Enoblituzumab

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT05708924 Apr 2023 → Aug 2024 fallopian tube cancer, ovarian cancer, peritoneum cancer Masonic Cancer Center, University of Minnesota Terminated No outcome recorded
Phase 1 NCT04630769 Apr 2021 → Jan 2022 fallopian tube adenocarcinoma, ovarian cancer, primary peritoneal carcinoma Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 1 NCT02982941 Dec 2016 → May 2019 Ewing sarcoma, Wilms tumor, desmoplastic small round cell tumor, neuroblastoma +2 MacroGenics Completed No outcome recorded
Phase 1 NCT02475213 Jul 2015 → Aug 2021 head and neck cancer, melanoma, non-small cell lung carcinoma, urothelial carcinoma MacroGenics Completed No outcome recorded
Phase 1 NCT02381314 Mar 2015 → Nov 2017 melanoma, non-small cell lung carcinoma MacroGenics Completed No outcome recorded
Phase 1 NCT01918930 Jul 2013 → Oct 2016 melanoma MacroGenics Terminated No outcome recorded
Phase 1 NCT01391143 Jul 2011 → Apr 2019 head and neck cancer, melanoma, non-small cell lung carcinoma, prostate cancer +3 MacroGenics Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06014255 Feb 2024 → Mar 2029 expected prostate cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting No outcome recorded
Phase 2 NCT04634825 Mar 2021 → Jul 2022 head and neck squamous cell carcinoma MacroGenics Terminated No outcome recorded
Phase 2 NCT02923180 Feb 2017 → Aug 2020 overdue prostate cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04129320 Oct 2019 → Oct 2020 head and neck squamous cell carcinoma MacroGenics Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Enoblituzumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634825
8

NCT04129320

NCT02923180

NCT02982941

NCT06014255

NCT05708924

NCT02475213

NCT02381314

NCT04630769

Known as MGA271 “Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer” NCT02381314
2

NCT01918930

NCT01391143

Modality Monoclonal antibody “Fc-optimized, humanized monoclonal antibodyNCT01391143
Route Intravenous “given by intravenous (IV) infusion” NCT01391143
Target CD276 “B7-H3 (CD276) is a member of the B7 family of cell surface molecules” PMID 35414591 Apr 2022